<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">63104</article-id><article-id pub-id-type="doi">10.7554/eLife.63104</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>Intrinsic OXPHOS limitations underlie cellular bioenergetics in leukemia</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-208479"><name><surname>Nelson</surname><given-names>Margaret A M</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-208480"><name><surname>McLaughlin</surname><given-names>Kelsey L</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-208481"><name><surname>Hagen</surname><given-names>James T</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-208482"><name><surname>Coalson</surname><given-names>Hannah S</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-208483"><name><surname>Schmidt</surname><given-names>Cameron</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-178332"><name><surname>Kassai</surname><given-names>Miki</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-208484"><name><surname>Kew</surname><given-names>Kimberly A</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-208485"><name><surname>McClung</surname><given-names>Joseph M</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-132009"><name><surname>Neufer</surname><given-names>P Darrell</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-208486"><name><surname>Brophy</surname><given-names>Patricia</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-208487"><name><surname>Vohra</surname><given-names>Nasreen A</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-208488"><name><surname>Liles</surname><given-names>Darla</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-208489"><name><surname>Cabot</surname><given-names>Myles C</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-207002"><name><surname>Fisher-Wellman</surname><given-names>Kelsey H</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0300-829X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Physiology</institution>, <institution>East Carolina University</institution>, <addr-line><named-content content-type="city">Greenville</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><institution content-type="dept">Biochemistry &amp; Molecular Biology</institution>, <institution>East Carolina University</institution>, <addr-line><named-content content-type="city">Greenville</named-content></addr-line>, <country>United States</country></aff><aff id="aff3"><institution content-type="dept">Surgery</institution>, <institution>East Carolina University</institution>, <addr-line><named-content content-type="city">Greenville</named-content></addr-line>, <country>United States</country></aff><aff id="aff4"><institution content-type="dept">Internal Medicine</institution>, <institution>East Carolina University</institution>, <addr-line><named-content content-type="city">Greenville</named-content></addr-line>, <country>United States</country></aff><aff id="aff5"><institution content-type="dept">Biochemistry and Molecular Biology</institution>, <institution>East Carolina University</institution>, <addr-line><named-content content-type="city">Greenville</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-10241"><name><surname>Topisirovic</surname><given-names>Ivan</given-names></name><role>Reviewing editor</role><aff><institution>Jewish General Hospital</institution>, <country>Canada</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>fisherwellmank17@ecu.edu</email> (KF);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>16</day><month>06</month><year>2021</year></pub-date><volume>10</volume><elocation-id>e63104</elocation-id><history><date date-type="received"><day>15</day><month>09</month><year>2020</year></date><date date-type="accepted"><day>16</day><month>06</month><year>2021</year></date></history><permissions><copyright-statement>© 2021, Nelson et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Nelson et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-63104-v1.pdf"/><abstract><p>Typified by oxidative phosphorylation (OXPHOS), mitochondria catalyze a wide variety of cellular processes seemingly critical for malignant growth. As such, there is considerable interest in targeting mitochondrial metabolism in cancer. However, notwithstanding the few drugs targeting mutant dehydrogenase activity, nearly all hopeful 'mito-therapeutics' cannot discriminate cancerous from non-cancerous OXPHOS and thus suffer from a limited therapeutic index. The present project was based on the premise that the development of efficacious mitochondrial-targeted anti-cancer compounds requires answering two fundamental questions: 1) is mitochondrial bioenergetics in fact different between cancer and non-cancer cells? and 2) If so, what are the underlying mechanisms? Such information is particularly critical for the subset of human cancers, including acute myeloid leukemia (AML), in which alterations in mitochondrial metabolism are implicated in various aspects of cancer biology (e.g., clonal expansion and chemoresistance). Herein, we leveraged an in-house diagnostic biochemical workflow to comprehensively evaluate mitochondrial bioenergetic efficiency and capacity in various hematological cell types, with a specific focus on OXPHOS dynamics in AML. Consistent with prior reports, clonal cell expansion, characteristic of leukemia, was universally associated with a hyper-metabolic phenotype which included increases in basal and maximal glycolytic and respiratory flux. However, despite having nearly 2-fold more mitochondria per cell, clonally expanding hematopoietic stem cells, leukemic blasts, as well as chemoresistant AML were all consistently hallmarked by intrinsic limitations in oxidative ATP synthesis (i.e., OXPHOS). Remarkably, by performing experiments across a physiological span of ATP free energy (i.e, ΔG<sub>ATP</sub>), we provide direct evidence that, rather than contributing to cellular ΔG<sub>ATP</sub>, leukemic mitochondria are particularly poised to consume ATP. Relevant to AML biology, acute restoration of OXPHOS kinetics proved highly cytotoxic to leukemic blasts, suggesting that active OXPHOS repression supports aggressive disease dissemination in AML. Taken together, these findings argue against ATP being the primary output of mitochondria in leukemia and provide proof-of-principle that restoring, rather than disrupting, OXPHOS and/or cellular ΔG<sub>ATP</sub> in cancer may represent an untapped therapeutic avenue for combatting hematological malignancy and chemoresistance.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100016156</institution-id><institution>U.S. Army Medical Research and Development Command</institution></institution-wrap></funding-source><award-id>W81XWH-19-1-0213</award-id><principal-award-recipient><name><surname>Fisher-Wellman</surname><given-names>Kelsey H</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>P01 CA171983</award-id><principal-award-recipient><name><surname>Cabot</surname><given-names>Myles C</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human subjects: All procedures involving human subjects were approved by the Institutional Review Board of the Brody School of Medicine at East Carolina University (study ID: UMCIRB 18-001328, UMCIRB 19-002331). For PBMC samples, healthy subjects (ages 18-70 years), without a prior history of hematological malignancy, were recruited from the surrounding area. Following informed consent (study ID: UMCIRB 18-001328), venous blood from the brachial region of the upper arm was collected. For primary leukemia samples, bone marrow aspirates were collected from patients undergoing confirmatory diagnosis for a range of hematological malignancies as a component of an already scheduled procedure. All patients provided informed consent prior to study enrollment (study ID: UMCIRB 19-002331).</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All data from the manuscript are available upon request. In addition, all data are available in the source data files provided with this paper. Raw data for proteomics experiments are available online using accession number &quot;PXD020715&quot; for Proteome Xchange and accession number &quot;JPST000934&quot; for jPOST Repository.</p></sec><supplementary-material><ext-link xlink:href="elife-63104-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>